US Macrolide Antibiotics Market

ID: MRFR/Pharma/16780-HCR
100 Pages
Satyendra Maurya
Last Updated: April 06, 2026
US Macrolide Antibiotics Market Research Report: Size, Share, Trend Analysis By Drugs (Azithromycin, Clarithromycin, Erythromycin, Fidaxomicin, Telithromycin), By Route of Administration (Oral, Parenteral), By Indication (Infection Due to Mycoplasma Pneumoniae, Legionella Sp, Bordetella Pertussis, Symptomatic Cat-Scratch Disease, Bacillary Angiomatosis, Peliosis Hepatis in Patients with AIDS, Cerebral Toxoplasmosis, Uncomplicated Skin Infections, Others) and By End Users (Hospitals, Dermatology Clinics, Pharmaceutical Companies, Others) - Growth Outlook & Industry Forecast 2025 To 2035
US Macrolide Antibiotics Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)13.6%
2024 Market Size$ 13.9 Billion
2025 Market Size$ 15.79 Billion
2035 Market Size$ 56.5 Billion
Key Players
Pfizer Inc
AstraZeneca PLC
Merck & Co Inc
Bristol-Myers Squibb Company
AbbVie Inc
Teva Pharmaceutical Industries Ltd
Trends
  • Rising Demand for Macrolide Antibiotics
  • Focus on Antibiotic Resistance
  • Innovation in Drug Formulations
Opportunities
  • Advancements in Pharmaceutical Research
  • Regulatory Support for Antibiotic Development
  • Increasing Prevalence of Respiratory Infections
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Food, Beverages & Nutrition, BY Drug (USD Billion)
      1. 4.1.1 Azithromycin
      2. 4.1.2 Clarithromycin
      3. 4.1.3 Erythromycin
      4. 4.1.4 Fidaxomicin
      5. 4.1.5 Telithromycin
    2. 4.2 Food, Beverages & Nutrition, BY Route of Administration (USD Billion)
      1. 4.2.1 Oral
      2. 4.2.2 Parenteral
    3. 4.3 Food, Beverages & Nutrition, BY Indication (USD Billion)
      1. 4.3.1 Infection Due to Mycoplasma Pneumoniae
      2. 4.3.2 Legionella Sp, or Bordetella Pertussis
      3. 4.3.3 Symptomatic Cat-Scratch Disease
      4. 4.3.4 Bacillary Angiomatosis
      5. 4.3.5 Peliosis Hepatis in Patients with AIDS
      6. 4.3.6 Cerebral Toxoplasmosis
      7. 4.3.7 Uncomplicated Skin Infections
      8. 4.3.8 Others
    4. 4.4 Food, Beverages & Nutrition, BY End User (USD Billion)
      1. 4.4.1 Hospitals
      2. 4.4.2 Dermatology Clinics
      3. 4.4.3 Pharmaceutical Companies
      4. 4.4.4 Others
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Pfizer Inc (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 AstraZeneca PLC (GB)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Merck & Co Inc (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Bristol-Myers Squibb Company (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 AbbVie Inc (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Teva Pharmaceutical Industries Ltd (IL)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Novartis AG (CH)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Sanofi S.A. (FR)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 GSK PLC (GB)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY DRUG
    3. 6.3 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    4. 6.4 US MARKET ANALYSIS BY INDICATION
    5. 6.5 US MARKET ANALYSIS BY END USER
    6. 6.6 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
    9. 6.9 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
    11. 6.11 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
    12. 6.12 FOOD, BEVERAGES & NUTRITION, BY DRUG, 2024 (% SHARE)
    13. 6.13 FOOD, BEVERAGES & NUTRITION, BY DRUG, 2024 TO 2035 (USD Billion)
    14. 6.14 FOOD, BEVERAGES & NUTRITION, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    15. 6.15 FOOD, BEVERAGES & NUTRITION, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
    16. 6.16 FOOD, BEVERAGES & NUTRITION, BY INDICATION, 2024 (% SHARE)
    17. 6.17 FOOD, BEVERAGES & NUTRITION, BY INDICATION, 2024 TO 2035 (USD Billion)
    18. 6.18 FOOD, BEVERAGES & NUTRITION, BY END USER, 2024 (% SHARE)
    19. 6.19 FOOD, BEVERAGES & NUTRITION, BY END USER, 2024 TO 2035 (USD Billion)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DRUG, 2025-2035 (USD Billion)
      2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. 7.2.3 BY INDICATION, 2025-2035 (USD Billion)
      4. 7.2.4 BY END USER, 2025-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Macrolide Antibiotics Market Segmentation

US Macrolide Antibiotics Market By Drug (USD Billion, 2025-2035)

  • Azithromycin
  • Clarithromycin
  • Erythromycin
  • Fidaxomicin
  • Telithromycin

US Macrolide Antibiotics Market By Route of Administration (USD Billion, 2025-2035)

  • Oral
  • Parenteral

US Macrolide Antibiotics Market By Indication (USD Billion, 2025-2035)

  • Infection Due to Mycoplasma Pneumoniae
  • Legionella Sp, or Bordetella Pertussis
  • Symptomatic Cat-Scratch Disease
  • Bacillary Angiomatosis
  • Peliosis Hepatis in Patients with AIDS
  • Cerebral Toxoplasmosis
  • Uncomplicated Skin Infections
  • Others

US Macrolide Antibiotics Market By End User (USD Billion, 2025-2035)

  • Hospitals
  • Dermatology Clinics
  • US Macrolide Antibiotics Market Companies
  • Others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.